Page last updated: 2024-12-05

succinylcholine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Succinylcholine: A quaternary skeletal muscle relaxant usually used in the form of its bromide, chloride, or iodide. It is a depolarizing relaxant, acting in about 30 seconds and with a duration of effect averaging three to five minutes. Succinylcholine is used in surgical, anesthetic, and other procedures in which a brief period of muscle relaxation is called for. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

succinylcholine : A quaternary ammonium ion that is the bis-choline ester of succinic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5314
CHEMBL ID703
CHEBI ID45652
SCHEMBL ID41537
MeSH IDM0020712

Synonyms (73)

Synonym
ditiline
AB00375912-06
2,2'-[(1,4-dioxobutane-1,4-diyl)bis(oxy)]bis(n,n,n-trimethylethanaminium)
succinyldicholine
succinic acid, diester with choline
diacetylcholine
hsdb 3254
brn 1805311
ethanaminium, 2,2'-((1,4-dioxo-1,4-butanediyl)bis(oxy))bis(n,n,n-trimethyl-
choline, succinate (2:1) (ester)
succinyl choline
choline, succinyl-
ethanaminium, 2,2'-((1,4-dioxo-1,4-butanediyl)bis(oxy))bis(n,n,n-trimethyl)-
choline, succinate (ester)
NCGC00015971-01
lopac-s-8251
LOPAC0_001080
succinylcholine
suxamethonium
306-40-1
C07546
DB00202
dicholine succinate
CHEBI:45652 ,
succinoylcholine
succinylbischoline
succinocholine
STK177290
NCGC00162336-01
2HA2
2HA6
HMS2090P14
NCGC00015971-03
succinate, dicholine
suxamethonium cation
CHEMBL703 ,
succinylcholine ion
suxamethonium ion
succinylcholine cation
L000926
axoizcjooaysmi-uhfffaoysa-
inchi=1/c14h30n2o4/c1-15(2,3)9-11-19-13(17)7-8-14(18)20-12-10-16(4,5)6/h7-12h2,1-6h3/q+2
trimethyl-[2-[4-oxo-4-(2-trimethylazaniumylethoxy)butanoyl]oxyethyl]azanium diio
2,2''-[(1,4-dioxobutane-1,4-diyl)bis(oxy)]bis(n,n,n-trimethylethanaminium)
bdbm50061568
trimethyl-[2-[4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl]oxyethyl]azanium
j2r869a8yf ,
unii-j2r869a8yf
4-04-00-01451 (beilstein handbook reference)
CCG-205157
smr000677912
MLS001183716
NCGC00015971-04
NCGC00015971-02
suxamethonium [who-dd]
succinylcholine [hsdb]
succinylcholine [vandf]
diester with choline
EPITOPE ID:116045
gtpl4004
trimethyl[2-({4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl}oxy)ethyl]azanium
AKOS022084126
SCHEMBL41537
DTXSID7048455 ,
ethanaminium,2,2'-[(1,4-dioxo-1,4-butanediyl)bis(oxy)]bis[n,n,n-trimethyl-
.succinylcholin
Q424378
NCGC00015971-07
succinylcholine-chloride
ethanaminium, 2,2'-((1.4-dioxo-1,4-butanediyl)bis(oxy))bis(n,n,n-trimethyl-
2,2'-((1,4-dioxobutane-1,4-diyl)bis(oxy))bis(n,n,n-trimethylethanaminium)
suxemethonium
dtxcid3028429

Research Excerpts

Overview

Succinylcholine is a neuromuscular block whose duration of action depends on rapid hydrolysis by butyrylcholinesterase (BChE) It is a popular muscle relaxant and one of its most common side effects is muscle fasciculation.

ExcerptReferenceRelevance
"Succinylcholine is a relaxant widely used but involves numerous complications."( Study of Rocuronium-Sugammadex as an Alternative to Succinylcholine-Cisatracurium in Microlaryngeal Surgery.
Aragón-Benedí, C; Fernández-Liesa, R; Martínez-Ubieto, J; Ortega-Lucea, S; Pascual-Bellosta, A; Visiedo-Sánchez, S, 2021
)
1.59
"Succinylcholine is a well-known neuromuscular blockade agent that is frequently used for rapid sequence intubation and short surgeries."( A Paralyzing Case of Myalgias.
Paquin, A; Schwartz, BC; Simard, C, 2020
)
1.28
"Succinylcholine is a preferred muscle relaxant for rapid sequence intubation. "( Impact of duloxetine on succinylcholine-induced postoperative myalgia after direct microlaryngoscopic surgeries: Randomized controlled double-blind study.
Ali Ibraheim, O; Herdan, R; Ibrahim, AK; Ibrahim, RAE; Mostafa, MF, 2022
)
2.47
"Succinylcholine is a short-term curare which degradation depends on its quick hydrolysis by butyrylcholinesterase (or pseudocholinesterase). "( [Prolonged curarisation following succinylcholine injection on butyrylcholinesterase deficiency and potentiated by a lithium treatment: a case report].
Commandeur, D; Drouillard, I; Huynh-Moynot, S; Moynot, JC; Ould-Ahmed, M; Thill, C,
)
1.85
"Succinylcholine (Sch) is a short-acting neuromuscular blocker medically used to achieve complete relaxation of muscle for a good intubation condition."( Homicide by Sch from a syringe-like dart ejected by a compound crossbow.
Guo, W; Luo, G; Meng, X; Wang, H, 2015
)
1.14
"Succinylcholine is a neuromuscular block whose duration of action depends on rapid hydrolysis by butyrylcholinesterase (BChE). "( [Prolonged neuromuscular block in a patient with butyrylcholinesterase deficiency].
Ceppa, F; Courcelle, S; Delacour, H; Hary, B; Mabboux, I, 2016
)
1.88
"Succinylcholine is a paralytic agent regularly utilized in anesthesia. "( Succinylcholine: a drug to avoid in bariatric surgery.
Conner, J; Dutson, E; Jensen, C; Lewis, CE; Mehran, A; Tejirian, T, 2009
)
3.24
"Succinylcholine is a popular muscle relaxant and one of its most common side effects is muscle fasciculation. "( Pretreatment with remifentanil is associated with less succinylcholine-induced fasciculation.
Arastheh, MT; Nasseri, K; Shami, S, 2010
)
2.05
"Succinylcholine is a depolarizing neuromuscular blocker frequently used during electroconvulsive therapy. "( Prolonged succinylcholine action during electroconvulsive therapy (ECT) after cytarabine, vincristine, and rituximab chemotherapy.
Aloysi, AS; Bryson, EO; Kellner, CH; Perez, AM; Popeo, D, 2011
)
2.21
"Succinylcholine is a low-potency drug with a very fast clearance that equilibrates relatively slowly with the effect compartment. "( Concentration-effect relation of succinylcholine chloride during propofol anesthesia.
Boismenu, D; Donati, F; Roy, JJ; Varin, F, 2002
)
2.04
"Succinylcholine (SUX) is a routinely used yet potentially lethal depolarizing muscle relaxant, the detection of which poses severe problems to the clinical or forensic analyst: within a few minutes after its in vivo administration, SUX is broken down via succinylmonocholine (SMC) to yield the endogenous substances succinic acid and choline. "( Synthesis and characterization of succinylcholine-d18 and succinylmonocholine-d3 designed for simultaneous use as internal standards in mass spectrometric analyses.
Kuepper, U; Madea, B; Musshoff, F, 2007
)
2.06
"Succinylcholine is a depolarizing muscle relaxant that has been used for five decades in clinical practice. "( [Prolonged apnea after administration of succinylcholine].
Bekvalac, M; Kolak, R; Pujić, B; Ziramov, J,
)
1.84
"Succinylcholine is a drug that causes blood potassium to increase. "( The effects of verapamil and diltiazem pretreatment on potassium release in dogs after the administration of succinylcholine.
Howie, MB; Kramer, MG; McSweeney, TD, 1998
)
1.96
"Succinylcholine is a short-acting depolarizing neuromuscular blocker used to facilitate intubation; pancuronium is a longer-acting, nondepolarizing agent commonly employed to control ventilation in pediatric patients. "( Pharmacology and use of muscle relaxants in infants and children.
Laravuso, R; Nugent, SK; Rogers, MC, 1979
)
1.7
"Succinylcholine is a short-acting depolarizing agent."( Clinical pharmacology of the neuromuscular blocking agents.
Gratz, I; Jacobi, AG; Larijani, GE; Silverberg, M, 1991
)
1
"Succinylcholine is a depolarizing neuromuscular blocking drug, which is rapidly hydrolyzed by the enzyme pseudocholinesterase. "( Pharmacodynamic properties of succinylcholine in greyhounds.
Curtis, MB; Eicker, SE, 1991
)
2.01
"Succinylcholine (Sch) which is a cholinergic neuromuscular blocker has been known to occasionally lead to episodes of malignant hyperthermia in swine and humans. "( Effects of succinylcholine and related substances administered into the medial preoptic area on the local EEG, body temperature, heart rate, galvanic skin resistance and biogenic amines.
Desiraju, T; Rau, M,
)
1.96

Effects

Succinylcholine has a fast onset, short duration of action, and is considered the choice for rapid sequence intubation. Succinyl choline has been indicted on account of the diverse risks associated with its administration.

ExcerptReferenceRelevance
"Succinylcholine has a fast onset, short duration of action, and is considered the choice for rapid sequence intubation. "( The Antioxidant Effect of Selenium on Succinylcholine-related Myalgia After Adult Sinuscopies: Randomized Controlled Double-Blind Trial.
Elkasem, MMA; Herdan, R; Mostafa, MF; Osman, EA; Seddik, MI, 2021
)
2.34
"Succinylcholine has a fast onset, short duration of action, and is considered the choice for rapid sequence intubation. "( The Antioxidant Effect of Selenium on Succinylcholine-related Myalgia After Adult Sinuscopies: Randomized Controlled Double-Blind Trial.
Elkasem, MMA; Herdan, R; Mostafa, MF; Osman, EA; Seddik, MI, 2021
)
2.34
"Succinylcholine use has been associated with several adverse events not reported with rocuronium."( Effect of Rocuronium vs Succinylcholine on Endotracheal Intubation Success Rate Among Patients Undergoing Out-of-Hospital Rapid Sequence Intubation: A Randomized Clinical Trial.
Adnet, F; Bounes, V; Broche, C; Chollet-Xémard, C; Combes, X; Deutsch, J; Ferdynus, C; Guihard, B; Huiart, L; Jabre, P; Lakhnati, P; Loeb, T; Marianne Dit Cassou, PJ; Ricard-Hibon, A; Rousseau, E; Savary, D; Tissier, C; Vivien, B; Wiel, E, 2019
)
1.54
"Succinylcholine has been increasingly used in the theft of animals. "( Simultaneous determination of succinylcholine and its metabolite in animal-derived foods by solid-phase extraction combined with ultra-performance liquid chromatography/mass spectrometry.
Fu, Y; Liu, S; Shi, M; Wang, H; Zhang, B, 2020
)
2.29
"Succinylcholine has numerous side effects."( [Muscle relaxants in the ICU].
Schneider, G, 2009
)
1.07
"Succinylcholine has been indicted on account of the diverse risks associated with its administration, which include hyperkalemia, vagal arrest, and malignant hyperthermia. "( Rapid sequence induction with rocuronium - a challenge to the gold standard.
Curley, GF, 2011
)
1.81
"Succinylcholine has been identified as the trigger agent, as other possible trigger agents were not involved."( Malignant hyperthermia: a case report in Thai Anesthesia Incidents Study (THAI Study).
Charuluxananan, S; Inphum, P; Kitsampanwong, W; Pulnitiporn, A, 2005
)
1.05
"Succinylcholine definitely has its use in anesthesia, but it is imperative for the provider to be discriminatory in its administration."( Probable succinylcholine-induced hyperkalemia in a trauma victim after recent benign anesthetics with succinylcholine.
Griner, RL; Tobin, JR, 1994
)
1.43
"Succinylcholine has been the agent of choice when clinical conditions require emergency airway protection during a rapid-sequence induction of anesthesia. "( Comparison of rocuronium, succinylcholine, and vecuronium for rapid-sequence induction of anesthesia in adult patients.
Flannery, KB; Magorian, T; Miller, RD, 1993
)
2.03
"Succinylcholine has long been the favored neuromuscular blocking agent for emergent airway management because of its rapid onset, dependable effect, and short duration. "( Succinylcholine: adverse effects and alternatives in emergency medicine.
Orebaugh, SL, 1999
)
3.19
"Succinylcholine (SCh) has been detected six months postmortem in liver, kidney, and injection site muscle of rats given 10 to 200 mg/kg by intramuscular injection. "( The influence of storage temperature and chemical preservation on the stability of succinylcholine in canine tissue.
Baldwin, KA; Forney, R, 1988
)
1.94

Actions

Succinylcholine is popular because its onset is faster than that of the nondepolarizing relaxants and metabolism by pseudocholinesterase clears it quickly. Succinyl choline is known to increase the tone of the masseter muscles.

ExcerptReferenceRelevance
"Succinylcholine seems to produce conditions that have higher satisfaction scores."( Rocuronium vs. succinylcholine in the emergency department: a critical appraisal.
Keim, SM; Mallon, WK; Shoenberger, JM; Walls, RM, 2009
)
1.43
"Both succinylcholine and seizures cause muscular injury during electroconvulsive therapy. "( Muscular injury after succinylcholine and electroconvulsive therapy.
Charuluxananan, S; Kyokong, O; Punyatavorn, S; Werawatganon, T, 2004
)
1.15
"Succinylcholine did not activate the neuronal nAChR subtypes alpha3beta2, alpha3beta4, alpha4beta2, or alpha7 at concentrations up to 1 mm and was a poor inhibitor at these receptor subtypes, with IC50 values above 100 microm."( Activation and inhibition of human muscular and neuronal nicotinic acetylcholine receptors by succinylcholine.
Dabrowski, M; Eriksson, LI; Fredholm, BB; Gurley, DA; Johnson, EC; Jonsson, M; Larsson, O, 2006
)
1.27
"Succinylcholine may cause dangerous arrhythmias in septic and immobilized children. "( Hyperkalemia and cardiac arrest following succinylcholine administration in a 16-year-old boy with acute nonlymphoblastic leukemia and sepsis.
Fendler, WM; Piotrowski, AJ, 2007
)
2.05
"Succinylcholine is known to increase the tone of the masseter muscles. "( Propofol reduces succinylcholine induced increase of masseter muscle tone.
Drewe, J; Hampl, KF; Kindler, C; Tschalèr, G; Ummenhofer, WC; Urwyler, A, 1998
)
2.08
"Succinylcholine is popular because its onset is faster than that of the nondepolarizing relaxants and metabolism by pseudocholinesterase clears it quickly."( Clinical pharmacology of neuromuscular blocking agents.
Fisher, DM, 1999
)
1.02

Treatment

ExcerptReferenceRelevance
"Pretreatment with succinylcholine produced persistent contraction of tissue and this response remained unaffected on subsequent treatment with Ach as well as ethanol."( On mechanism of action of ethanol-induced contraction of frog rectus abdominis.
Kela, AK; Mehta, SC; Mehta, VL; Sharma, AK; Srivastava, AK, 1994
)
0.61

Toxicity

Intravenous succinylcholine (SCh) is widely used as a muscle relaxant. It is often associated with adverse effects, including muscle fasciculations, postoperative myalgia, elevated serum potassium (K+) and creatine phosphokinase (CPK), etc.

ExcerptReferenceRelevance
"Neuromuscular, circulatory, and adverse effects of intravenous succinylcholine (SCh), mg/kg, were compared in 3 groups of 40 patients each."( Diazepam prevents some adverse effects of succinylcholine.
Fahmy, NR; Lappas, DG; Malek, NS, 1979
)
0.76
"There have been reports of toxic reactions to ester-type local anesthetics in patients with genetic anomalies of plasma cholinesterase in so-called dibucaine-resistant homozygotes or heterozygotes."( Survey of local anesthetic toxicity in the families of patients with atypical plasma cholinesterase.
Eilderton, TE; Zsigmond, EK, 1975
)
0.25
" Increasing SCh dosage with pretreatment apparently did not accentuate adverse effects, and in some instances was associated with fewer such effects, than after lower-dose SCh injections without pretreatment."( Adverse effects of increased succinylcholine dose following d-tubocurarine pretreatment.
Peterson, C; Stoelting, RK,
)
0.42
"Intravenous succinylcholine (SCh) is widely used as a muscle relaxant but it is often associated with adverse effects, including muscle fasciculations, postoperative myalgia, elevated serum potassium (K+) and creatine phosphokinase (CPK), etc."( [The study of pretreatment with diphenylhydantoin or D-tubocurarine on succinylcholine-induced adverse effects].
Ho, ST; Hu, OY; Hwing, CS; Kuo, WS; Li, CH, 1990
)
0.89
" Mivacurium is a non-depolarizing muscle relaxant with a relatively rapid onset and a short duration of action, and to date it has been proved safe in MH-susceptible patients."( Neuroleptic malignant syndrome and mivacurium: a safe alternative to succinylcholine?
Brull, SJ; Kelly, D, 1994
)
0.52
" Adverse effects of suxamethonium are generally related to its agonist mode of action."( Adverse effects of depolarising neuromuscular blocking agents. Incidence, prevention and management.
Abel, M; Book, WJ; Eisenkraft, JB, 1994
)
0.29
"(1) To investigate changes in arterial oxygen saturation via pulse oximeter (SpO2) during apnea and after reinstitution of manual ventilation at SpO2 of 95% or 90% following rapid sequence induction of anesthesia in children after 2-minute preoxygenation; (2) to determine whether the setting of a safe threshold of apneic period to an SpO2 of 95% is appropriate in children during anesthetic induction; and (3) to evaluate the influences of age, body weight, and height on the time from the start of apnea to SpO2 of 95%."( Study of the safe threshold of apneic period in children during anesthesia induction.
An, G; Deng, XM; Liao, X; Luo, LK; Tong, SY; Xue, FS, 1996
)
0.29
"The safe threshold of an apneic period setting to an SpO2 of 95% was appropriate in children during anesthesia induction."( Study of the safe threshold of apneic period in children during anesthesia induction.
An, G; Deng, XM; Liao, X; Luo, LK; Tong, SY; Xue, FS, 1996
)
0.29
"Among all the drugs used for general anesthesia, neuromuscular blockers appear to play a prominent role in the incidence of severe adverse reactions."( Adverse effects of neuromuscular blockers and their antagonists.
Magboul, MM; Naguib, M, 1998
)
0.3
" There were no neonatal adverse effects in either group based on: Apgar scores at 1 and 5 min; times to sustained respiration; neuroadaptive capacity scores at 15 min, 2 h and 24 h; and umbilical venous and arterial blood-gas values and acid-base status."( Rapacuronium for modified rapid sequence induction in elective caesarean section: neuromuscular blocking effects and safety compared with succinylcholine, and placental transfer.
Abboud, TK; Abboud, TS; Abouleish, EI; Bikhazi, G; Kenaan, CA; Lee, J; Mroz, L; Zhu, J, 1999
)
0.51
" Succinylcholine may be appropriate and safe for use in certain patients with moderate hyperkalemia."( Can succinylcholine be used safely in hyperkalemic patients?
Gan, TJ; Lubarsky, DA; Olson, RP; Schow, AJ, 2002
)
1.78
" The use of the basophil activation marker CD63 as a screening tool in selecting a safe muscle relaxant is presented."( Anaphylaxis to vecuronium: the use of basophil CD63 expression as a possible screening tool to identify a safe alternative.
Appadurai, IR; Sudheer, PS, 2007
)
0.34
" We aimed to determine the adverse events during neonatal intubation using the most commonly used premedication regimen in the UK."( Endotracheal intubation in a neonatal population remains associated with a high risk of adverse events.
Anandaraj, J; Arasu, A; Chaudhary, R; Clarke, P; Curley, A; Malviya, M; Ponnusamy, V; Venkatesh, V, 2011
)
0.37
" Adverse events were reported in 87."( Safety and Efficacy of Rocuronium With Sugammadex Reversal Versus Succinylcholine in Outpatient Surgery-A Multicenter, Randomized, Safety Assessor-Blinded Trial.
de Bie, J; Egan, TD; Jahr, JS; Pavlin, J; Philip, BK; Rowe, E; Sabo, D; Soto, R; Woo, T,
)
0.37
" The safe preparation of medications during resuscitation requires attention, time and resources, and can be a source of medication error."( Predrawn prehospital medications are microbiologically safe for up to 48 hours.
Foster, A; Garner, A; Gutierrez, CH; Kitcher, J; Soeyland, T; Vidler, S, 2018
)
0.48
"Predrawing of the eight studied medications for urgent prehospital procedures appears to be a microbiologically safe practice with syringe dwell times up to 48 hours."( Predrawn prehospital medications are microbiologically safe for up to 48 hours.
Foster, A; Garner, A; Gutierrez, CH; Kitcher, J; Soeyland, T; Vidler, S, 2018
)
0.48
" Unfortunately, a variety of (sometimes lethal) adverse effects, such as hyperkalemia and cardiac arrest, are associated with its use, and currently there are no specific antidotes to reverse Sch or to treat these side-effects."( Supramolecular therapeutics to treat the side effects induced by a depolarizing neuromuscular blocking agent.
Cheng, Q; Huang, F; Li, C; Li, L; Li, S; Shangguan, L; Wang, R; Zhang, J; Zhang, X, 2019
)
0.51
" Broader use can reveal unknown adverse effects and impact the life cycle significantly."( A Chronology for the Identification and Disclosure of Adverse Effects of Succinylcholine.
Desai, MS; Huang, L; Sang, CN, 2019
)
0.75
"Initial clinical testing in humans in 1952 found no adverse effects on cardiovascular or respiratory systems."( A Chronology for the Identification and Disclosure of Adverse Effects of Succinylcholine.
Desai, MS; Huang, L; Sang, CN, 2019
)
0.75
"Particularly given the regulatory environment of the time, BW Co appropriately reported the adverse effects of succinylcholine after market entry; it updated promotional and packaging material in a timely manner to reflect newly discovered adverse effects."( A Chronology for the Identification and Disclosure of Adverse Effects of Succinylcholine.
Desai, MS; Huang, L; Sang, CN, 2019
)
0.96
"Due to longer procedure duration and an unfavorable side effect profile, etomidate appears inferior to methohexital as an anesthetic agent in mECT despite longer seizure durations."( Comparison of etomidate and methohexital as anesthetic agents for continuation and maintenance electroconvulsive therapy: A retrospective analysis of seizure quality and safety.
Baldinger-Melich, P; Eder, V; Frey, R; Kress, HG; Michalek-Sauberer, A; Millischer, V; Pramhas, S; Rujescu, D; Wiedermann, I, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
"To study the effects of succinylcholine on subsequent pharmacodynamics of nondepolarizing muscle relaxants, a comparative pharmacodynamic study was carried out in patients having balanced anesthesia (thiopental, fentanyl, nitrous oxide/oxygen) in whom equipotent doses of pipecuronium (80 micrograms/kg) and pancuronium (100 micrograms/kg) were given with or without prior administration of succinylcholine (1 mg/kg)."( Effects of succinylcholine on the pharmacodynamics of pipecuronium and pancuronium.
Dubois, MY; Fleming, NW; Lea, DE, 1991
)
0.98
" These estimates of the pharmacokinetic parameters of atracurium are markedly different from those derived from pharmacokinetic analysis of single bolus dose data."( Pharmacokinetics of atracurium during continuous infusion.
Beemer, GH; Bjorksten, AR; Crankshaw, DP, 1990
)
0.28
" The only significant difference in the pharmacokinetic parameters was the shortened elimination half-life in patients between 1 and 3 years of age."( Pharmacokinetics of glycopyrrolate in children.
Ali-Melkkilä, T; Iisalo, E; Kaila, T; Kanto, J; Olkkola, KT; Rautakorpi, P,
)
0.13
" The shortened elimination half-life in children between 1 and 3 years of age is of minor clinical importance."( Pharmacokinetics of glycopyrrolate in children.
Ali-Melkkilä, T; Iisalo, E; Kaila, T; Kanto, J; Olkkola, KT; Rautakorpi, P,
)
0.13
" The pharmacokinetic parameters were (SCh 1, n = 8 and 2 mg/kg, n = 6): apparent volume of distribution (16."( Pharmacokinetics of succinylcholine in man.
Hashimoto, Y; Hoshi, K; Matsukawa, S, 1993
)
0.61
" The recorded drug effect was used in a non-linear curve fitting technique to derive estimates of the pharmacokinetic and pharmacodynamic parameters."( Pharmacokinetics and pharmacodynamics of suxamethonium.
Donohue, P; Graham, GG; Torda, TA; Warwick, NR, 1997
)
0.3
" Detection of SUX as well as its metabolite succinylmonocholine (SMC) is difficult: both substances are analytically challenging, and the extremely short plasma half-life of SUX additionally hampers detection of the parent compound."( Pharmacokinetic properties of succinylmonocholine in surgical patients.
Herbstreit, F; Hilger, RA; Kuepper, U; Madea, B; Musshoff, F, 2011
)
0.37

Compound-Compound Interactions

ExcerptReferenceRelevance
" Drugs which inhibit cholinesterase activity or which inhibit acetylcholine release or synthesis may produce prolonged respiratory paralysis when combined with succinylcholine."( Succinylcholine drug interactions during electroconvulsive therapy.
Marco, LA; Randels, PM, 1979
)
1.9
" Also, neuromuscular effects of enflurane in combination with dTc or pancuronium are not significantly different from those seen suring equi-MAC isoflurane anesthesia."( Neuromuscular effects of enflurane, alone and combined with d-Tubocurarine, pancuronium, and succinylcholine, in man.
Fogdall, RP; Miller, RD, 1975
)
0.47

Bioavailability

ExcerptReferenceRelevance
" It is concluded that hyaluronidase increases the rate of absorption of succinylcholine chloride."( The effects of hyaluronidase on the immobilization of goats by intramuscular succinylcholine chloride.
McLaughlin, HJ; Ohanesian, N; Swaim, SF; Ward, FP, 1969
)
0.71

Dosage Studied

The potency estimates for succinylcholine in obese adolescents are comparable to those in similarly aged nonobese adolescents when dosing is calculated based on total body mass and not lean body mass. On a weight basis neonates and young infants are resistant to both depolarizing and non-depolarizing muscle relaxants.

ExcerptRelevanceReference
" The dose-response curve to suxamethonium in tetrodotoxin 2 X 10(-7)M could be shifted to the right with tubocurarine 10(-6)M."( A mammalian muscle with the pharmacological characteristics of slow tonic muscle.
Dale, MM; Muid, R, 1978
)
0.26
"The protection against bradycardia afforded by atropine given intravenously just prior to a second dose of suxamethonium during halothane inhalation anaesthesia was studied in 100 healthy, adult patients randomly allocated to one of five groups characterized by dosage of atropine."( Halothane anaesthesia and suxamethonium III. Atropine 30 s before a second dose of suxamethonium during inhalation anaesthesia: effects and side-effects.
Brandt, MR; Viby-Mogensen, J, 1978
)
0.26
"5 to 1 microgram/kg) than by increasing the dosage of thiopental."( The role of different components of balanced anaesthesia in tolerance to endotracheal intubation.
Aromaa, U; Tammisto, T, 1977
)
0.26
" The authors conclude that succinylcholine administered repeatedly at this dosage is not contraindicated in patients with renal failure."( The effect of repeated doses of succinylcholine on serum potsssium in patients with renal failure.
Miller, R; Powell, DR,
)
0.71
" There were no fasciculations with this dosage and conditions for endotracheal intubation were excellent."( Inhibition of suxamethonium relaxation by tubocurarine and gallamine pretreatment during induction of anaesthesia in man.
Pauca, AL; Reynolds, RC; Strobel, GE, 1975
)
0.25
" When dosage was calculated on a surface area basis, there was a linear relationship for infants and children as a single group between the log dose and the times to recover to 50 and 90 per cent neuromuscular transmission."( Neuromuscular blocking effects of succinylcholine in infants and children.
Cook, DR; Fisher, CG, 1975
)
0.53
" Increasing SCh dosage with pretreatment apparently did not accentuate adverse effects, and in some instances was associated with fewer such effects, than after lower-dose SCh injections without pretreatment."( Adverse effects of increased succinylcholine dose following d-tubocurarine pretreatment.
Peterson, C; Stoelting, RK,
)
0.42
"Intraocular pressure (IOP) measurements were made in a series of 92 male surgical patients, to assess the effects of timing and dosage of succinylcholine given after a standardized sleep dose of thiopental (3 mg."( Thiopental and succinylcholine: Action on intraocular pressure.
Bruce, DL; Joshi, C,
)
0.69
" All these compounds led to abnormalities of the cervical vertebrae; at higher dosage interference with normal morphogenesis involved the whole vertebral column."( Cholinomimetic teratogens: studies with chicken embryos.
Landauer, W, 1975
)
0.25
" The influence of prior suxamethonium administration on the potency of Org 9426 was studied also by constructing a dose-response curve."( Comparison of intubating conditions after administration of Org 9246 (rocuronium) and suxamethonium.
Boules, Z; Clarke, RS; Cooper, R; Mirakhur, RK, 1992
)
0.28
" Other 191 patients were divided into three groups according to the type and dosage of pretreatment as follows: VB 20 micrograms."( [Influence of small doses of vecuronium and pancuronium on succinylcholine-induced neuromuscular blockade].
Nishizawa, M, 1990
)
0.52
" Also, the dose-response relationships of pancuronium and succinylcholine in surgical patients during anesthesia with desflurane (n = 13) were compared to those during isoflurane anesthesia (n = 14)."( The neuromuscular effects of desflurane, alone and combined with pancuronium or succinylcholine in humans.
Caldwell, JE; Eger, EI; Heier, T; Laster, MJ; Lynam, DP; Magorian, T; Weiskopf, RB; Yasuda, N, 1991
)
0.75
" The relative cutaneous histamine-releasing ability of each drug was derived from calculated dose-response relationships."( Comparative cutaneous histamine release by neuromuscular blocking agents.
Galletly, DC, 1986
)
0.27
" In the patients in the groups II and III the hydrocortisone in the blood, taken 1 minute before induction and 3 minutes after intubation was dosed radioimmunologically."( [Hemodynamic reaction in the ultrarapid induction and protection realized with fentanyl].
Acalovschi, I; Fleşeru, M; Szabo, P; Szilagy, E,
)
0.13
" Prior administration of succinylcholine was associated with a leftward shift of dose-response curve of vecuronium or pancuronium."( [The effect of succinylcholine on vecuronium and pancuronium].
Kosaka, F; Manabe, N; Morita, K; Ohta, Y; Ono, K, 1989
)
0.93
" They were treated uniformly with respect to premedication, anesthesia, venipuncture (cubital), and concentration (1%) and dosage (1 mg/kg) of succinylcholine (SCh)."( [The rate of injection of succinylcholine and onset of neuromuscular action, serum potassium or myoglobin levels. Studies in men during halothane anesthesia].
Braun, J; Kutz, N; Plötz, J; Sommerburg, C, 1989
)
0.78
"Single dose-response curves were determined for suxamethonium in neonates, infants and children during thiopentone-fentanyl-nitrous oxide anaesthesia."( Dose-response curves for suxamethonium in neonates, infants and children.
Baker, RD; McKiernan, EP; Meakin, G; Morris, P, 1989
)
0.28
" Although the time to maximum NMB following divided doses of pancuronium, atracurium or vecuronium is significantly longer than that for succinylcholine, divided dosing significantly decreases the time required to reach maximal NMB."( Accelerated onset of non-depolarizing neuromuscular blocking drugs: pancuronium, atracurium and vecuronium. A comparison with succinylcholine.
Gergis, SD; Mehta, MP; Sokoll, MD, 1988
)
0.68
"This study was performed to determine the potency of succinylcholine using the single-dose technique, and to test the ability of the cumulative dose technique for generating dose-response data."( Dose-response curves for succinylcholine: single versus cumulative techniques.
Bevan, DR; Donati, F; Smith, CE, 1988
)
0.83
" A combination of the two drugs both in "standard" and modified dosage resulted in the greatest reduction in the wheal and flare."( Effect of terfenadine and ranitidine on histamine and suxamethonium wheals.
Bödeker, RH; Paul, E; Pfeffer, M, 1988
)
0.27
" Then dose-response curves for both muscles were constructed using incremental doses of succinylcholine with an infusion to replace metabolized or redistributing drug."( Potency of succinylcholine at the diaphragm and at the adductor pollicis muscle.
Bevan, DR; Donati, F; Smith, CE, 1988
)
0.89
"Intubating conditions following 2 different dosage levels of atracurium, a new non-depolarising muscle relaxant was compared with suxamethonium."( Conditions for endotracheal intubation after atracurium and suxamethonium.
Famewo, CE, 1986
)
0.27
" Wide variation occurred from subject to subject in the succinylcholine versus GS dose-response curve position."( Effects of succinylcholine on respiratory and nonrespiratory muscle strength in humans.
Bourke, DL; Williams, JP, 1985
)
0.91
" Secondly, cats chronically were treated with 2 mg X kg-1 of intramuscular hydrocortisone three times a week for 1 month, and then dose-response curves were constructed for pancuronium or succinylcholine."( The effects of acute and chronic hydrocortisone treatment on neuromuscular blockade in the anesthetized cat.
Briscoe, JR; Durant, NN; Katz, RL, 1984
)
0.46
" No evidence supporting the concept that dosage should be related to patient's weight was found."( Reduction of post-suxamethonium pain by pretreatment with four non-depolarizing agents.
Bennetts, FE; Khalil, KI, 1981
)
0.26
" On a weight basis neonates and young infants are resistant to both depolarizing and non-depolarizing muscle relaxants; when dosage is calculated on the basis of surface area neonates and young infants are not resistant to succinylcholine, but appear sensitive to non-depolarizing relaxants."( Muscle relaxants in infants and children.
Cook, DR, 1981
)
0.45
" Use of a nerve stimulator facilitates more appropriate and individualized dosage of the neuromuscular blocking agents."( [Testing of neuromuscular function during anaesthesia (author's transl)].
Chraemmer-Jørgensen, B; Hicquet, J; Howardy-Hansen, P; Ording, H; Viby-Mogensen, J, 1980
)
0.26
" Cumulative dose-response curves to SCh were shifted to the right in a nearly parallel manner by (+)- and (-)-propranolol which were about equiactive."( Curare-like effect of propranolol on rat extraocular muscles.
Chiarandini, DJ, 1980
)
0.26
"Cumulative dose-response curves of suxamethonium, tubocurarine, and pancuronium were constructed in 142 patients under enflurane and halothane anesthesia, and neuroleptic anesthesia (control group)."( Differential increase in potency of neuromuscular blocking agents by enflurane and halothane.
Schuh, FT, 1983
)
0.27
"Succinylcholine was administered by infusion to halothane-anesthetized ponies to determine dosage requirements for surgical relaxation up to 3 hours' duration."( Succinylcholine infusion associated with hyperthermia in ponies anesthetized with halothane.
Hildebrand, SV; Howitt, GA, 1983
)
3.15
" Atypical pseudocholinesterases were identified using quantitative dosage of enzymatic activity and inhibition of atypical pseudocholinesterases by dibucaine, fluoride, chloride, scoline and urea."( [Congenital anomaly of serum pseudocholinesterase originating in neonatal respiratory distress].
Canis, M; Gutknecht, JL; Haberer, JP; Monteillard, C; Schoeffler, P; Viallard, JL, 1984
)
0.27
" Dose-response curves for pancuronium, duration of blockade, and adequacy of relaxation for tracheal intubation did not differ between patients receiving midazolam (N = 10) or thiopental (N = 10)."( Comparison of thiopental and midazolam on the neuromuscular responses to succinylcholine or pancuronium in humans.
Cronnelly, R; Miller, RD; Morris, RB, 1983
)
0.5
"In the light of studies on the duration of action and pharmacokinetics of intravenous neostigmine, it is recommended that, depending upon the dosage administered, at least 1 hour should elapse before a depolarizer can safely be given after neuromuscular reversal with neostigmine, and at least 90 - 120 minutes after reversal with physostigmine."( Administration of depolarizing muscle relaxants after non-depolarizer reversal: when is it safe?
De Roubaix, JA, 1982
)
0.26
" Comparison of the results with those from 15 patients given suxamethonium 50 mg showed that atracurium in this dosage took longer to produce complete ablation of the twitch responses but that it lasted longer (about 40 min)."( Use of atracurium during general surgery monitored by the train-of-four stimuli.
Hunter, JM; Jones, RS; Utting, JE, 1982
)
0.26
" Although a higher dosage of Tramadol reduces significantly the supplementary barbiturate dosage per kilogram bodyweight per minute which is required, it has no effect on the incidence of reflex movements, nor does it prevent the marked intraoperative rise of diastolic blood pressure."( [The clinical usefulness of Tramadol-infusion anaesthesia (author's transl)].
Rothhammer, A; Skrobek, W; Weis, KH, 1981
)
0.26
"The potencies of suxamethonium, pancuronium, and tubocurarine were increased, as shown by a parallel shift to the left of cumulative dose-response curves, following normovolaemic haemodilution before operation."( Influence off haemodilution on the potency of neuromuscular blocking drugs.
Schuh, FT, 1981
)
0.26
" Single dose-response curves were determined by probit analysis."( Dose-response studies of the interaction between mivacurium and suxamethonium.
Abdulatif, M; al-Ghamdi, A; Naguib, M; Selim, M, 1995
)
0.29
"To study the neuromuscular interactions between succinylcholine (Sch) and esmolol, we determined the dose-response relationship of Sch and the neuromuscular actions of the 3xED90 dose of Sch, both prior to and following esmolol pretreatment."( Neuromuscular interactions between succinylcholine and esmolol in the rat.
Chang, RY; Chern, SC; Chiang, YY; Liou, MD; Tsai, SK; Tseng, KF, 1994
)
0.82
" These findings have implications for electrical dosing in right unilateral ECT."( Possible impact of stimulus duration on seizure threshold in ECT.
Jarvis, MR; Rasmussen, KG; Zorumski, CF, 1994
)
0.29
" One alternative is the combination of glycopyrrolate, alfentanil and suxamethonium described here, although the ideal medication and dosage still remain to be defined."( Physiological changes, plasma beta-endorphin and cortisol responses to tracheal intubation in neonates.
Koivisto, M; Pokela, ML, 1994
)
0.29
" Mechanical difficulties such as trouble gaining intravenous access and medicinal problems such as inappropriate dosing were rare."( Procedural complications of electroconvulsive therapy: assessment and recommendations.
Haas, S; Lippmann, S; Quast, G, 1993
)
0.29
" No difference in intubation scores or number of intubation attempts among the three dosage groups were found."( Intubating conditions and neuromuscular effects of mivacurium during propofol-alfentanil anaesthesia.
Crul, JF; Ory, JP; Van Aken, H; Vandermeersch, E; Vertommen, JD, 1995
)
0.29
" We recommend no alteration in dosing of either SCh or ND NMBs in patients with NF-1."( Responses to nondepolarizing neuromuscular blockers and succinylcholine in von Recklinghausen neurofibromatosis.
Rawoof, SA; Richardson, MG; Setty, GK, 1996
)
0.54
" This study investigated whether (1) the relative responses of muscles is inverted between succinylcholine (SUX) and vecuronium (VEC), and (2) differences in dose-response or duration of action are related to the morphology of fibres, endplates and acetylcholine receptors (AChR) in muscles."( Duration of succinylcholine and vecuronium blockade but not potency correlates with the ratio of endplate size to fibre size in seven muscles in the goat.
Donati, F; Ibebunjo, C; Srikant, CB, 1996
)
0.89
"In goats during thiopentone anaesthesia, the evoked EMG response to indirect train-of-four stimulation was monitored and the cumulative dose-response curves and duration of action of SUX and VEC in the diaphragm, cricoary-tenoideus dorsalis, thyroarytenoideus, transversus abdominis, rectus abdominis, soleus and gastrocnemius muscles were determined and related to their fibre composition, fibre size, endplate size, endplate to fibre size ratio, AChR number or AChR density by regression analysis."( Duration of succinylcholine and vecuronium blockade but not potency correlates with the ratio of endplate size to fibre size in seven muscles in the goat.
Donati, F; Ibebunjo, C; Srikant, CB, 1996
)
0.67
" The 50% and 90% inhibitory concentrations (IC50, IC90) of Vb, d-Tc and SCh were determined form dose-response curves."( [Neuromuscular effects of vecuronium d-tubocurarine and succinylcholine in malnourished rat's diaphragm].
Tajiri, O, 1996
)
0.54
" There were 13 reported cardiac arrests (requiring external cardiac massage), three of which were associated with repeat dosing and one with undiagnosed Duchenne muscular dystrophy."( Routine suxamethonium in children. A regional survey of current usage.
Jerwood, DC; Robinson, AL; Stokes, MA, 1996
)
0.29
"We have compared the dose-response relationships of suxamethonium, mivacurium and atracurium and examined the interactions of suxamethonium with mivacurium or atracurium in humans by isobolographic analysis."( Interactions between suxamethonium and mivacurium or atracurium.
Chon, SU; Kim, KS; Na, DJ, 1996
)
0.29
" Twelve to 18 hr after the last gavage of tacrine or saline, and -20 min after iv tacrine, cumulative dose-response curves of succinylcholine were determined in the tibialis and soleus muscles in anaesthetized, ventilated rats during monitoring of evoked twitch response to indirect (nerve) train-of-four stimulation."( Tacrine does not alter the potency of succinylcholine in the rat.
Donati, F; Eshelby, D; Fox, GS; Ibebunjo, C; Tchervenkov, JI, 1997
)
0.77
" However, because maturational changes in certain of these characteristics counterbalance, dosing requirements do not differ markedly with age."( Neuromuscular blocking agents in paediatric anaesthesia.
Fisher, DM, 1999
)
0.3
"The potency estimates for succinylcholine in obese (body mass index > 30 kg/m(2)) adolescents are comparable to those in similarly aged nonobese adolescents when dosing is calculated based on total body mass and not lean body mass."( The potency of succinylcholine in obese adolescents.
Katz, MS; Rose, JB; Theroux, MC, 2000
)
0.96
" Potency and efficacy were derived from nonlinear fittings of the dose-response curves."( Different patterns of mast cell activation by muscle relaxants in human skin.
Blunk, JA; Koppert, W; Petersen, LJ; Rentsch, K; Schmelz, M; Skov, P, 2001
)
0.31
"For succinylcholine and the isoquinolines, dose-response curves for the vascular and sensory effects paralleled the histamine and tryptase release."( Different patterns of mast cell activation by muscle relaxants in human skin.
Blunk, JA; Koppert, W; Petersen, LJ; Rentsch, K; Schmelz, M; Skov, P, 2001
)
0.87
" Possible side-effects due to the chemical structure and the necessary dosage for intubation of different agents are also discussed."( [Clinical administration of muscle relaxants for intubation].
Hofmockel, R; Nöldge-Schomburg, G; Pohl, B, 2001
)
0.31
" The successful treatment is based on an early diagnosis, immediately interruption of triggering agents, intravenous administration of Dantrolene in sufficient dosage and starting of adequate symptomatic treatment."( [Malignant hyperthermia].
Ben Ammar, MS; Bouhajja, B; Haddad, F, 2002
)
0.31
"The aim of this study was to compare the outcomes associated with two differing right unilateral (RUL) electroconvulsive therapy (ECT) dosing protocols: 2-3X seizure threshold (2-3X ST) and fixed high dose (FHD) at 353 mC."( A naturalistic comparison of two right unilateral electroconvulsive therapy dosing protocols: 2-3X seizure threshold versus fixed high-dose.
Frost, AD; Kelly, M; Lush, P; Ward, WK, 2006
)
0.33
" Higher succinylcholine dosage is followed by lower incidence of myalgia."( Which muscle relaxants should be used in day surgery and when.
Bettelli, G, 2006
)
0.77
" The onset depends on the dosage used."( Rapid sequence intubation: a review of recent evidences.
Di Filippo, A; Gonnelli, C, 2009
)
0.35
" Some statisticians now consider this approach outmoded and assert that non-linear regression (NLR) is the preferred way to analyse sigmoidal dose-response relationships."( Determining the potency of neuromuscular blockers: are traditional methods flawed?
Kopman, AF; Lien, CA; Naguib, M, 2010
)
0.36
"We analysed raw data for succinylcholine, rocuronium, rapacuronium, and cisatracurium from previously published studies using both LRA and NLR to determine the ED(50) and ED(95) values and the respective slopes of the dose-response relationships."( Determining the potency of neuromuscular blockers: are traditional methods flawed?
Kopman, AF; Lien, CA; Naguib, M, 2010
)
0.66
"Succinylcholine and rocuronium are equivalent with regard to first-attempt intubation success in the ED when dosed according to the ranges used in this study."( Comparison of succinylcholine and rocuronium for first-attempt intubation success in the emergency department.
Erstad, BL; Patanwala, AE; Sakles, JC; Stahle, SA, 2011
)
2.17
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
" A variety of medications have been used for RSI, with potential for inadequate or excessive dosing as well as complications including hypotension and the need for redosing."( A standardized rapid sequence intubation protocol facilitates airway management in critically injured patients.
Anderson, S; Ballow, SL; Chang, M; Kaups, KL, 2012
)
0.38
" The dosing of postintubation sedative and analgesic infusions were compared 30 min after initiation between the two groups."( Comparison of rocuronium and succinylcholine on postintubation sedative and analgesic dosing in the emergency department.
Goddard, LA; Korinek, JD; Patanwala, AE; Sakles, JC; St John, AE; Thomas, RM, 2014
)
0.69
" Denervation time and stage and the type of neuromuscular blocker and dosage should be taken into consideration when using these drugs in patients with nerve injury."( Receptor analysis of differential sensitivity change to succinylcholine induced by nerve injury in rat gastrocnemius.
Jiang, JH; Li, ST; Song, JC; Yang, B, 2015
)
0.66
" Rocuronium-neostigmine combination is a safe alternative if appropriately dosed (0."( Minimum Effective Doses of Succinylcholine and Rocuronium During Electroconvulsive Therapy: A Prospective, Randomized, Crossover Trial.
Bittner, EA; Cusin, C; Doran, ME; Eikermann, M; Guchelaar, HJ; MacDonald, TO; Mirzakhani, H; Nozari, A; Welch, CA, 2016
)
0.73
"There are limited data regarding appropriateness of sedative and paralytic dosing of obese patients undergoing rapid sequence intubation (RSI) in the emergency department."( Accuracy of rapid sequence intubation medication dosing in obese patients intubated in the ED.
Bhat, R; Dynin, M; Goyal, M; Mazer-Amirshahi, M; Sun, C; Tefera, E; Towle, D; Vaughns, J, 2016
)
0.43
" Dosing for succinylcholine and etomidate was calculated as milligrams per kilogram of total body weight (TBW) for each patient, defining appropriate dosing as succinylcholine 1-1."( Accuracy of rapid sequence intubation medication dosing in obese patients intubated in the ED.
Bhat, R; Dynin, M; Goyal, M; Mazer-Amirshahi, M; Sun, C; Tefera, E; Towle, D; Vaughns, J, 2016
)
0.81
" Most obese and nonobese patients were inappropriately dosed with RSI medications, suggesting that physicians are not dosing these medications based on weight."( Accuracy of rapid sequence intubation medication dosing in obese patients intubated in the ED.
Bhat, R; Dynin, M; Goyal, M; Mazer-Amirshahi, M; Sun, C; Tefera, E; Towle, D; Vaughns, J, 2016
)
0.43
" Succinylcholine dosing was titrated to an appropriate level to avoid prolonged apnea in subsequent ECT treatments."( Electroconvulsive Therapy Considerations for Transgendered Patients.
Adams, DC; Balla, A; Grondin, LS; O'Donnell, SE; Tran, BK; Tsai, MH, 2017
)
1.37
" First pass success can be increased by ensuring correct dosing for overweight patients and employing the use of video laryngoscope."( Nursing Considerations When Using Neuromuscular Blocking Agents to Assist With Intubation: A Review of Literature.
Blauvelt, G; Burdick, K; Cannon, EJ,
)
0.13
" Recent studies in the adult emergency medicine literature have highlighted both delays in time to administration of PIS and subtherapeutic dosing of sedative agents in the emergency department."( The Administration of Postintubation Sedation in the Pediatric Emergency Department.
Berg, K; Cosgrove, P; Gregg, V; Wilkinson, M, 2021
)
0.62
" These studies showed that preanesthetic neuromuscular monitoring can be used for precise NMBA dosing in myasthenia gravis patients."( Mapping the current evidence on the anesthetic management of adult patients with neuromuscular disorders-a scoping review.
Gubbels, M; Heytens, L; Jungbluth, H; Riazi, S; Snoeck, MMJ; van den Bersselaar, LR; Voermans, NC, 2022
)
0.72
" The dosage of the active principle was measured using high-pressure liquid chromatography coupled with ultraviolet detection."( Impact of Ambient Temperature on 5 Emergency Drugs Aboard an Emergency Medical Car Over a 1-Year Period.
Marson, C; Roschel, K; Schneider, S; Stammet, P; Welter, C, 2022
)
0.72
" Rocuronium, when dosed appropriately, provides neuromuscular blockade as quickly and effectively as succinylcholine but was previously avoided due to its prolonged duration of action which precluded neurologic examination."( Traumatic brain injury and RSI is rocuronium or succinylcholine preferred?
Dao, AQ; Kuza, C; Mohapatra, S; Moon, TS, 2023
)
1.38
" Additional prospective studies are needed to determine optimal induction agent selection and dosing in patients presenting with shock or sepsis."( Pharmacotherapy optimization for rapid sequence intubation in the emergency department.
Brown, CS; Engstrom, K; Lyons, N; Mattson, AE; Rech, MA, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
neuromuscular agentA drug used for its actions on skeletal muscle.
muscle relaxantA drug used to produce muscle relaxation (excepting neuromuscular blocking agents). Its primary clinical and therapeutic use is the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. Also used for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in multiple sclerosis.
drug allergenAny drug which causes the onset of an allergic reaction.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
quaternary ammonium ionA derivative of ammonium, NH4(+), in which all four of the hydrogens bonded to nitrogen have been replaced with univalent (usually organyl) groups.
succinate esterA carboxylic ester resulting from the esterification of one or both of the carboxy groups of succinic acid. (Succinate ester in which only one of the carboxy groups of succinic acid has been esterified are known as hemisuccinates.)
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thioredoxin reductaseRattus norvegicus (Norway rat)Potency1.58490.100020.879379.4328AID588453
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency10.00000.035520.977089.1251AID504332
D(1A) dopamine receptorHomo sapiens (human)Potency2.81840.02245.944922.3872AID488983
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AcetylcholinesteraseMus musculus (house mouse)Ki21.00000.00001.42829.3000AID404437
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, AcetylcholinesteraseMus musculus (house mouse)Kd35.000022.0000297.2000930.0000AID977611
Chain A, AcetylcholinesteraseMus musculus (house mouse)Kd35.000022.0000297.2000930.0000AID977611
Chain A, AcetylcholinesteraseMus musculus (house mouse)Kd35.000022.0000297.2000930.0000AID977611
Chain A, AcetylcholinesteraseMus musculus (house mouse)Kd35.000022.0000297.2000930.0000AID977611
Chain A, AcetylcholinesteraseMus musculus (house mouse)Kd35.000022.0000297.2000930.0000AID977611
Chain A, AcetylcholinesteraseMus musculus (house mouse)Kd35.000022.0000297.2000930.0000AID977611
Chain A, AcetylcholinesteraseMus musculus (house mouse)Kd35.000022.0000297.2000930.0000AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (53)

Assay IDTitleYearJournalArticle
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID219385Inhibition of stimulated vagus nerve-induced bradycardia in anesthetized cats; ND means not data2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID219534Dose causing 50% block of muscle twitch in isolated chick biventer cervicis muscle (Decrease in baseline tension)2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID219382Inhibitory potency in anesthetized cats2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID404437Inhibition of mouse AChE2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors.
AID219389Duration (90%) measured for NMB activity in anesthetized cats2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID126469Inhibitory potency in anesthetized rhesus monkeys2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID219391Recovery time (25-75 %) measured for NMB activity in anesthetized cats2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID127145Recovery time (25-75 %) measured for NMB activity in anesthetized rhesus monkeys2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID208872Stimulation of ion flux in TE671 cells1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Neuronal nicotinic acetylcholine receptors as targets for drug discovery.
AID625278FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of no concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID219381Inhibition of superior cervical nerve-induced contractions of the nictitating membrane in anesthetized cats; Pre- and post-block increases in twitch tension and short-lived muscle fasciculations 20-30 s after dosing2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID219390Onset time was measured for NMB activity in anesthetized cats2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID127134Onset time was measured for NMB activity in anesthetized rhesus monkeys2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID126970Duration (90%) measured for NMB activity in anesthetized rhesus monkeys2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID71786Agonist efficacy was evaluated as concentration that produces 10-m V depolarization in frog sartorius muscle.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Synthetic and conformational studies on anatoxin-a: a potent acetylcholine agonist.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1811Experimentally measured binding affinity data derived from PDB2006The Journal of biological chemistry, Sep-29, Volume: 281, Issue:39
Substrate and product trafficking through the active center gorge of acetylcholinesterase analyzed by crystallography and equilibrium binding.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2006The Journal of biological chemistry, Sep-29, Volume: 281, Issue:39
Substrate and product trafficking through the active center gorge of acetylcholinesterase analyzed by crystallography and equilibrium binding.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5,778)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903969 (68.69)18.7374
1990's838 (14.50)18.2507
2000's508 (8.79)29.6817
2010's371 (6.42)24.3611
2020's92 (1.59)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 77.90

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index77.90 (24.57)
Research Supply Index8.86 (2.92)
Research Growth Index4.26 (4.65)
Search Engine Demand Index143.51 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (77.90)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials600 (9.26%)5.53%
Reviews334 (5.16%)6.00%
Case Studies830 (12.82%)4.05%
Observational13 (0.20%)0.25%
Other4,699 (72.56%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (39)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
General vs. Intrathecal Anesthesia Fort Total Knee Arthroplasty; a Randomized Clinical Trial [NCT01312298]120 participants (Actual)Interventional2011-08-31Completed
A Double-Blind, Randomized, Crossover Design Study To Compare The Rocuronium Reversal By Sugammadex To Succinylcholine For Electroconvulsive Therapy (ECT) [NCT03532178]Phase 244 participants (Actual)Interventional2019-01-01Completed
Can Mini-dose Succinylcholine Accelerate Lung Collapse and Intrathoracic Nerve Blocks During Nonintubated Thoracoscopic Surgery? A Randomized Controlled Trial [NCT03469323]30 participants (Anticipated)Interventional2018-03-31Recruiting
Ventilation by Mask Before and After the Administration of Neuromuscular Blockade: a Non-inferiority Trial [NCT02237443]Phase 4210 participants (Actual)Interventional2014-08-31Completed
Standardised Drug Provocation Testing in Perioperative Hypersensitivity [NCT06065137]Phase 450 participants (Anticipated)Interventional2023-10-31Not yet recruiting
General Anesthesia Versus Sedation During Intra-arterial Treatment for Stroke [NCT02822144]Phase 3351 participants (Actual)Interventional2016-09-29Completed
The Effect of Precurarization With Rocuronium on the Incidence and Severity of Succinylcholine-Induced Fasciculations and Myalgias in a High Volume ERCP Center [NCT04581395]Phase 3300 participants (Actual)Interventional2020-10-02Completed
Rapid Sequence Intubation With Rocuronium-Sugammadex Compared With Succinylcholine [NCT00953550]Phase 461 participants (Actual)Interventional2009-09-30Completed
A Single Blinded Multicenter Randomized Study Comparing Intubating Conditions During Rapid Sequence Induction With Either Suxamethonium 1.0 mg/kg or Rocuronium 1.0 mg/kg in Elderly Patients (≥ 80 Years Old) [NCT04868409]Phase 490 participants (Anticipated)Interventional2021-08-12Recruiting
Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome [NCT05658692]Phase 41,000 participants (Anticipated)Interventional2022-10-01Recruiting
Prevention of Brad Arrhythmia Induced by Repeated Succinylcholine by Atropine Sulfate During Gynecological Laparoscopic Surgery: a Randomized Controlled Trial [NCT02676011]Phase 2120 participants (Actual)Interventional2016-02-29Completed
Structural Brain Plasticity in Elderly Depressed Patients Following Electroconvulsive Therapy [NCT02667353]110 participants (Actual)Interventional2011-06-30Completed
Remifentanil and Atropine for Intubation in Neonates; a Randomized Controlled Trial [NCT00815048]Phase 430 participants (Actual)Interventional2006-01-31Completed
Phase 4 Study of Succinylcholine Versus Rocuronium as Neuromuscular Blocking Agent for Emergency Intubation in Intensive Care [NCT00355368]Phase 4420 participants (Actual)Interventional2006-08-31Completed
Comparing Intubating Conditions and Patient Satisfaction Using Succinylcholine or Low-dose Rocuronium for Rigid Bronchoscopy: A Randomized Study [NCT01902641]105 participants (Actual)Interventional2011-10-31Completed
Effect of Succinylcholine on Patients Using Statins [NCT00986583]70 participants (Actual)Interventional2009-09-30Completed
[NCT01966484]100 participants (Anticipated)Interventional2013-10-31Completed
Comparing Intubating Conditions Using Succinylcholine or Rocuronium/Sugammadex for Rigid Bronchoscopy: a Randomized Study [NCT01996358]150 participants (Anticipated)Interventional2015-08-31Suspended
Succinylcholine vs Rocuronium for Prehospital Emergency Intubation : a Randomized Trial [NCT02000674]Phase 31,321 participants (Actual)Interventional2013-12-31Completed
Impact of Closely Grouped, Iterative Exposures to Suxamethonium During Electroconvulsive Therapy (ECT) on the Sensitization to Neuro-Muscular Blocking Agents (NMBA) and the Development of Protective Antibodies [NCT05210062]70 participants (Anticipated)Observational2022-01-27Recruiting
A Multicenter, Randomized, Parallel Group, Comparative, Active-Controlled, Safety-Assessor Blinded, Phase IIIa, Trial, in Adult Subjects Comparing Recovery From 1.2 mg.Kg-1 Rocuronium Followed by 16 mg.Kg-1 Org 25969 at 3 Minutes With Recovery From 1.0 mg [NCT00474253]Phase 3115 participants (Actual)Interventional2006-02-10Completed
Validation of Inspiratory Muscle Pressure Estimation and Automated Detection of Asynchronies in Patients Under Assisted Mechanical Ventilation [NCT05820347]50 participants (Actual)Interventional2022-08-26Completed
Characterizing Fade Upon Train-of Four Stimulation During Onset and Offset of Neuromuscular Block Produced by Succinlycholine [NCT02425449]Phase 419 participants (Actual)Interventional2015-04-30Completed
Prospective, Randomized Trial Comparing Effect of General Anesthesia With and Without Neuromuscular Blockade on Postoperative Pulmonary Complications in Elective Cardiac Surgical Patients [NCT02635542]Phase 4100 participants (Actual)Interventional2016-03-31Completed
Comparison Between Standalone Succinyl Choline and Rocuronium After Pretreatment With Dexmedetomidine, in Rapid Sequence Induction. [NCT04709315]Phase 3240 participants (Anticipated)Interventional2020-10-01Enrolling by invitation
A Single Dose of Etomidate During Rapid Sequence Induction in Trauma Patients Causes Significant Adrenocortical Insufficiency: A Prospective Randomized Study [NCT00462644]30 participants (Actual)Interventional2006-02-28Completed
Modern Myorelaxation Procedure and Reversal of Neuromuscular Blockade With General Anesthesia for Caesarean Section [NCT01718236]Phase 4500 participants (Actual)Interventional2012-09-30Completed
Use of Neuromuscular Blocking Agents and Neuromuscular Monitoring in 7 Danish Teaching Hospitals - a Cross-sectional Study [NCT02914119]30,430 participants (Actual)Observational [Patient Registry]2016-10-01Completed
High-Resolution Solid-State Manometry of the Effect of Succinylcholine on Barrier Pressure [NCT05556408]Phase 414 participants (Actual)Interventional2015-03-01Completed
Rapid Sequence Intubation With Magnesium-rocuronium Compared With Succinylcholine - A Randomised Clinical Study [NCT01571908]Phase 2280 participants (Actual)Interventional2012-09-30Completed
Interventional Rigid Bronchoscopy Under General Anesthesia: Influence of the Muscle Relaxant, Succinylcholine or Rocuronium, on the Quality of the Surgical Procedure [NCT01579864]Phase 46 participants (Actual)Interventional2012-01-31Terminated(stopped due to recent publication (Ghezel-Ahmadi. Thorac Cardiovasc Surg. 2014 Nov 21))
Comparison of Intubation Conditions During Rapid Sequence Induction Obtained With Modified Time Principal Induction With a Standard Intubation Dose of Rocuronium Versus Succinylcholine : A Prospective Non-inferiority Randomized and Blind Trial [NCT06029049]Phase 4152 participants (Anticipated)Interventional2023-09-13Recruiting
To Explore the Influence of Different Anesthesia Induction Schemes on the Quality and Clinical Effect of Electroconvulsive Convulsions in Patients With Depression Based on EEG Monitoring [NCT05900245]24 participants (Anticipated)Interventional2023-06-12Recruiting
Optimal Control of Muscle Strength for Electroconvulsive Therapy: A Comparison of Succinylcholine Versus Rocuronium-induced Neuromuscular Blockade [NCT01441960]45 participants (Actual)Interventional2011-05-31Completed
A Double-blind, Randomized, Parallel Design Study to Compare Surgical Conditions for Fetus Delivery and Suture of the Uterus and Abdominal Wall in Cesarean Section Under General Anesthesia With Deep Neuromuscular Blockade Versus Succinylcholine [NCT01941628]Phase 491 participants (Actual)Interventional2014-08-16Completed
A Multi-center, Randomized, Parallel Group, Comparative, Active Controlled, Safety Assessor Blinded Trial in Adult Subjects Comparing Rocuronium Plus Sugammadex Versus Succinylcholine Alone in Subjects Undergoing Short Surgical Procedures in Out-patient S [NCT00751179]Phase 3161 participants (Actual)Interventional2008-11-30Completed
Transversus Abdominis Plane (TAP) Block for Laparoscopic Appendicectomy in Children: Opioid Saving and Alternative in the Curarization [NCT02505841]240 participants (Anticipated)Interventional2015-05-31Active, not recruiting
"Randomized, Parallel Group, Controlled Trial to Compare Two Different NMB + Reversal Strategies in Adult Obese Patients Undergoing Laparoscopic Abdominal Surgery" [NCT02410590]Phase 40 participants (Actual)Interventional2015-07-31Withdrawn
A Randomised Controlled Trial of Standard Bilateral Electroconvulsive Therapy Versus High-dose Unilateral Electroconvulsive Therapy for Severe Depression [NCT01907217]Phase 4138 participants (Actual)Interventional2008-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00355368 (4) [back to overview]Number of Participants Exhibiting Desaturation >5%
NCT00355368 (4) [back to overview]Number of Participants With an Failed First Intubation Attempts
NCT00355368 (4) [back to overview]Quality of Intubation Conditions Using a Validated Score: Viby-Mogensen et al. Good Clinical Research Practice (GCRP) in Pharmacodynamic Studies of Neuromuscular Blocking Agents. Acta Anaesthesiol Scand 1996;40:59-74.
NCT00355368 (4) [back to overview]Time to Completion of Intubation
NCT00462644 (7) [back to overview]Postintubation Cortisol (Baseline Cortisol Level)
NCT00462644 (7) [back to overview]Change in Baseline Cortisol
NCT00462644 (7) [back to overview]Cortisol Level 60 Minutes After Cortisol Stimulating Test (CST)
NCT00462644 (7) [back to overview]Hospital Length of Stay
NCT00462644 (7) [back to overview]Intensive Care Unit (ICU) Length of Stay
NCT00462644 (7) [back to overview]Ventilator Days
NCT00462644 (7) [back to overview]Number of Deaths
NCT00474253 (7) [back to overview]Time to Recovery of T1 to 10% of Baseline Value From Start of Rocuronium + Sugammadex or Succinylcholine Administration
NCT00474253 (7) [back to overview]Time to Recovery of T1 to 90% of Baseline Value From Start of Rocuronium + Sugammadex or Succinylcholine Administration
NCT00474253 (7) [back to overview]Level of Consciousness: Number of Participants Arousable With Minimal Stimulation
NCT00474253 (7) [back to overview]Level of Consciousness: Number of Participants Awake and Oriented
NCT00474253 (7) [back to overview]Level of Consciousness: Number of Participants Responsive Only to Tactile Stimulation
NCT00474253 (7) [back to overview]Number of Participants Able to Perform 5-Second Head Lift
NCT00474253 (7) [back to overview]Number of Participants Experiencing General Muscle Weakness
NCT00751179 (11) [back to overview]Change From Baseline in Plasma Potassium Levels at 10 Minutes After Treatment With Sugammadex
NCT00751179 (11) [back to overview]Number of Participants With at Least One Adverse Event (AE) in Rocuronium - Sugammadex and Succinylcholine Treatment Groups
NCT00751179 (11) [back to overview]Change From Baseline in Plasma Potassium Levels at 10 Minutes After Treatment With Rocuronium or Succinylcholine
NCT00751179 (11) [back to overview]Change From Baseline in Plasma Potassium Levels at 15 Minutes After Treatment With Rocuronium or Succinylcholine
NCT00751179 (11) [back to overview]Change From Baseline in Plasma Potassium Levels at 15 Minutes After Treatment With Sugammadex
NCT00751179 (11) [back to overview]Change From Baseline in Plasma Potassium Levels at 2 Minutes After Treatment With Rocuronium or Succinylcholine
NCT00751179 (11) [back to overview]Change From Baseline in Plasma Potassium Levels at 2 Minutes After Treatment With Sugammadex
NCT00751179 (11) [back to overview]Change From Baseline in Plasma Potassium Levels at 5 Minutes After Treatment With Rocuronium or Succinylcholine
NCT00751179 (11) [back to overview]Change From Baseline in Plasma Potassium Levels at 5 Minutes After Treatment With Sugammadex
NCT00751179 (11) [back to overview]Time to Recovery of T1 to 90% of Baseline Following Neuromuscular Blockade Induced by Succinylcholine
NCT00751179 (11) [back to overview]Time to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9 Following Administration of 4.0 mg/kg of Sugammadex After Neuromuscular Blockade Induced by Rocuronium
NCT00986583 (6) [back to overview]Muscle Pain
NCT00986583 (6) [back to overview]Plasma Myoglobin Concentration
NCT00986583 (6) [back to overview]Serum Potassium Concentration
NCT00986583 (6) [back to overview]Change in Plasma Creatine Phosphokinase (CK) Concentration From 2 to 24 Hours Postoperatively
NCT00986583 (6) [back to overview]Duration of Succinylcholine Block
NCT00986583 (6) [back to overview]Fasciculation
NCT01441960 (3) [back to overview]Compound Specific Differences in Time to Recovery From Neuromuscular Blockade
NCT01441960 (3) [back to overview]Differences in Seizure Duration Between Compounds
NCT01441960 (3) [back to overview]Optimal Dose of Neuromuscular Blocking Agent During ECT
NCT01907217 (4) [back to overview]Columbia Autobiographical Memory Interview-Short Form (AMI-SF)
NCT01907217 (4) [back to overview]Columbia Autobiographical Memory Interview-Short Form (AMI-SF)
NCT01907217 (4) [back to overview]Columbia Autobiographical Memory Interview-Short Form (AMI-SF)
NCT01907217 (4) [back to overview]Hamilton Depression Rating Scale (HDRS)
NCT01941628 (3) [back to overview]Number of Participants With Newborn in Need of Respiratory Support
NCT01941628 (3) [back to overview]Peroperative and Postoperative Surgical Complication
NCT01941628 (3) [back to overview]Induction to Delivery Interval
NCT02425449 (1) [back to overview]Fade on Train of Four Stimulation
NCT02635542 (2) [back to overview]Surgical Conditions
NCT02635542 (2) [back to overview]Number of Participants With Postoperative Pulmonary Complications
NCT02914119 (2) [back to overview]Last Recorded Train-of-four (TOF) Ratio Before Tracheal Extubation or Removal of Supraglottic Airway Device in Patients Receiving a Non-depolarizing NMBA
NCT02914119 (2) [back to overview]Time in Minutes From Tracheal Extubation or Removal of Supraglottic Airway Device to Discharge From Post-anaesthesia Care Unit in Cases Involving a Non-depolarizing NMBA With and Without Neuromuscular Monitoring, Respectively
NCT03532178 (2) [back to overview]Recovery Time of T1 to 90% Baseline
NCT03532178 (2) [back to overview]Number of Participants With Treatment or Emergent Adverse Events of the Drugs

Number of Participants Exhibiting Desaturation >5%

decrease of >5% in oxygen saturation measured continuously using pulse oxymetry (NCT00355368)
Timeframe: at any time between the start of the intubation sequence and 2min after the completion of intubation

Interventionparticipants (Number)
Succinylcholine73
Rocuronium66

[back to top]

Number of Participants With an Failed First Intubation Attempts

defined as either uncompleted intubation attempt within 90 sec or starting a second intubation attempt (NCT00355368)
Timeframe: within the first 90 sec following the start of induction

Interventionparticipants (Number)
Succinylcholine32
Rocuronium36

[back to top]

Quality of Intubation Conditions Using a Validated Score: Viby-Mogensen et al. Good Clinical Research Practice (GCRP) in Pharmacodynamic Studies of Neuromuscular Blocking Agents. Acta Anaesthesiol Scand 1996;40:59-74.

"The factors laryngoscopy, vocal cords, and response to intubation are individually rated with a score from 1 (bad intubation conditions)to 3 (excellent intubation conditions)and the resulting three scores are summed up. The maximum score is thus 9 while the minimum score is 3.~Units: measure on a scale" (NCT00355368)
Timeframe: during laryngoscopy and the first minute after completion of intubation

Interventionscore points (Mean)
Succinylcholine8.3
Rocuronium8.2

[back to top]

Time to Completion of Intubation

time interval between the injection of the induction agent and the first appearance of endtidal CO2 (NCT00355368)
Timeframe: time interval between the injection of the induction agent and the first appearance of endtidal CO2

Interventionseconds (Mean)
Succinylcholine81
Rocuronium95

[back to top]

Postintubation Cortisol (Baseline Cortisol Level)

cortisol level after randomization and rapid sequence induction (NCT00462644)
Timeframe: postintubation (baseline cortisol level)

Interventionmicrograms/dL (Mean)
Etomidate18.2
Fentanyl-Midazolam27.9

[back to top]

Change in Baseline Cortisol

change from baseline cortisol (drawn prior to RSI) to 2nd cortisol level (4-6hrs after RSI, but before stim test) (NCT00462644)
Timeframe: 4-6hr after RSI

Interventionmicrograms/dL (Mean)
Etomidate-12.8
Fentanyl-Midazolam1.1

[back to top]

Cortisol Level 60 Minutes After Cortisol Stimulating Test (CST)

(NCT00462644)
Timeframe: 60 minutes after administration of cotrosyn

Interventionmicrograms/dL (Mean)
Etomidate22.91
Fentanyl-Midazolam39.09

[back to top]

Hospital Length of Stay

days from admission to hospital discharge (NCT00462644)
Timeframe: time to hospital discharge in days

Interventiondays (Mean)
Etomidate13.9
Fentanyl-Midazolam6.4

[back to top]

Intensive Care Unit (ICU) Length of Stay

ICU length of stay in days (NCT00462644)
Timeframe: time from hospital admission to transfer out of ICU to floor bed

Interventiondays (Mean)
Etomidate8.1
Fentanyl-Midazolam3.0

[back to top]

Ventilator Days

(NCT00462644)
Timeframe: time from intubation to extubation

Interventiondays (Mean)
Etomidate6.3
Fentanyl-Midazolam1.5

[back to top]

Number of Deaths

deaths (NCT00462644)
Timeframe: death in hospital

Interventionparticipants (Number)
Etomidate2
Fentanyl-Midazolam0

[back to top]

Time to Recovery of T1 to 10% of Baseline Value From Start of Rocuronium + Sugammadex or Succinylcholine Administration

Neuromuscular functioning was monitored by applying repetitive Train-Of-Four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 refers to the amplitude (height) of the first twitch after TOF nerve stimulation. (NCT00474253)
Timeframe: Up to 15 minutes after administration of rocuronium + sugammadex or succinylcholine

InterventionMinutes (Mean)
Rocuronium + Sugammadex4.35
Succinylcholine7.15

[back to top]

Time to Recovery of T1 to 90% of Baseline Value From Start of Rocuronium + Sugammadex or Succinylcholine Administration

Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 refers to the amplitude (height) of the first twitch after TOF nerve stimulation. (NCT00474253)
Timeframe: Up to 20 minutes after administration of rocuronium + sugammadex or succinylcholine

InterventionMinutes (Mean)
Rocuronium + Sugammadex6.13
Succinylcholine11.03

[back to top]

Level of Consciousness: Number of Participants Arousable With Minimal Stimulation

The number of participants aroused with minimal stimulation was assessed as part of an overall assessment of level of consciousness. The level of consciousness was used as a measure of recovery from neuromuscular blockade at two time points: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. Attempts were made to arouse participants every 15 minutes with mild prodding, mild shaking, and asking questions regarding name, location, and day of the week. The assessment ended once the participant was awake and fully orientated. (NCT00474253)
Timeframe: Up to 24 hours after administration of rocuronium + sugammadex or succinylcholine

,
InterventionParticipants (Count of Participants)
Prior to transfer to recovery roomPrior to discharge from recovery room
Rocuronium + Sugammadex71
Succinylcholine152

[back to top]

Level of Consciousness: Number of Participants Awake and Oriented

The number of participants who were awake and oriented was assessed as part of an overall assessment of the clinical level of consciousness. The clinical level of consciousness was used as a measure of recovery from neuromuscular blockade at two time points: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. Attempts were made to arouse participants every 15 minutes with mild prodding, mild shaking, and asking questions regarding name, location, and day of the week. The assessment ended once the participant was awake and fully orientated. (NCT00474253)
Timeframe: Up to 24 hours after administration of rocuronium + sugammadex or succinylcholine

,
InterventionParticipants (Count of Participants)
Prior to transfer to recovery roomPrior to discharge from recovery room
Rocuronium + Sugammadex819
Succinylcholine1333

[back to top]

Level of Consciousness: Number of Participants Responsive Only to Tactile Stimulation

The number of participants responsive only to tactile stimulation was assessed as part of an overall assessment of the level of consciousness. The level of consciousness was used as a measure of recovery from neuromuscular blockade at two time points: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. Attempts were made to arouse participants every 15 minutes with mild prodding, mild shaking, and asking questions regarding name, location, and day of the week. The assessment ended once the participant was awake and fully orientated. (NCT00474253)
Timeframe: Up to 24 hours after administration of rocuronium + sugammadex or succinylcholine

,
InterventionParticipants (Count of Participants)
Prior to transfer to recovery roomPrior to discharge from recovery room
Rocuronium + Sugammadex50
Succinylcholine70

[back to top]

Number of Participants Able to Perform 5-Second Head Lift

The number of participants who were able to lift their head for 5 seconds was assessed as a measure of recovery following neuromuscular blockade at two time points: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. The assessment was performed every 15 minutes until the first successful 5-second head lift was achieved. (NCT00474253)
Timeframe: Up to 24 hours after administration of rocuronium + sugammadex or succinylcholine

,
InterventionParticipants (Count of Participants)
Prior to transfer to recovery roomPrior to discharge from recovery room
Rocuronium + Sugammadex1320
Succinylcholine2435

[back to top]

Number of Participants Experiencing General Muscle Weakness

The number of participants experiencing general muscle weakness was assessed by the investigator as a measure of recovery from neuromuscular blockade at two time points: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. The assessments were performed every 15 minutes until the absence of general muscle weakness. A standardized examination form was used to determine the presence or absence of muscle weakness in various muscle groups. (NCT00474253)
Timeframe: Up to 24 hours after administration of rocuronium + sugammadex or succinylcholine

,
InterventionParticipants (Count of Participants)
Prior to transfer to recovery roomPrior to discharge from recovery room
Rocuronium + Sugammadex20
Succinylcholine30

[back to top]

Change From Baseline in Plasma Potassium Levels at 10 Minutes After Treatment With Sugammadex

"Change from baseline = 10 minutes post dose value - baseline value. Baseline levels were obtained prior to rocuronium dose. Only data post sugammadex dose are included for rocuronium - sugammadex group. The change from baseline interval included most or all of the intubation/surgical period for sugammadex analysis (since sugammadex was administered at the end of the surgical procedure) but not for succinylcholine or rocuronium analyses (since these were administered immediately after the baseline measurement just prior to intubation/commencement of the surgical period)." (NCT00751179)
Timeframe: Baseline and 10 minutes post dose

Interventionmmol/L (Mean)
Rocuronium - Sugammadex0.07

[back to top]

Number of Participants With at Least One Adverse Event (AE) in Rocuronium - Sugammadex and Succinylcholine Treatment Groups

"Only AEs which occurred following administration of sugammadex or succinylcholine are included. AEs in the rocuronium - sugammadex group occurring after rocuronium but before sugammadex administration are considered pretreatment events and are not included. The AE reporting interval included the entire intubation/surgical period for the succinylcholine group (since succinylcholine was administered just prior to intubation/commencement of surgery) but not for the rocuronium - sugammadex group (since sugammadex was administered at the end of the surgical procedure)." (NCT00751179)
Timeframe: Up to 7 days post dose

Interventionparticipants (Number)
Rocuronium - Sugammadex60
Succinylcholine75

[back to top]

Change From Baseline in Plasma Potassium Levels at 10 Minutes After Treatment With Rocuronium or Succinylcholine

"Change from baseline = 10 minutes post dose value - baseline value. Baseline levels were obtained prior to rocuronium or succinylcholine dose. Only data post rocuronium dose are included for rocuronium - sugammadex group. The change from baseline interval included most or all of the intubation/surgical period for sugammadex analysis (since sugammadex was administered at the end of the surgical procedure) but not for succinylcholine or rocuronium analyses (since these were administered immediately after the baseline measurement just prior to intubation/commencement of the surgical period)." (NCT00751179)
Timeframe: Baseline and 10 minutes post dose

Interventionmmol/L (Mean)
Rocuronium - Sugammadex-0.01
Succinylcholine0.32

[back to top]

Change From Baseline in Plasma Potassium Levels at 15 Minutes After Treatment With Rocuronium or Succinylcholine

"Change from baseline = 15 minutes post dose value - baseline value. Baseline levels were obtained prior to rocuronium or succinylcholine dose. Only data post rocuronium dose are included for rocuronium - sugammadex group. The change from baseline interval included most or all of the intubation/surgical period for sugammadex analysis (since sugammadex was administered at the end of the surgical procedure) but not for succinylcholine or rocuronium analyses (since these were administered immediately after the baseline measurement just prior to intubation/commencement of the surgical period)." (NCT00751179)
Timeframe: Baseline and 15 minutes post dose

Interventionmmol/L (Mean)
Rocuronium - Sugammadex0.02
Succinylcholine0.33

[back to top]

Change From Baseline in Plasma Potassium Levels at 15 Minutes After Treatment With Sugammadex

"Change from baseline = 15 minutes post dose value - baseline value. Baseline levels were obtained prior to rocuronium dose. Only data post sugammadex dose are included for rocuronium - sugammadex group. The change from baseline interval included most or all of the intubation/surgical period for sugammadex analysis (since sugammadex was administered at the end of the surgical procedure) but not for succinylcholine or rocuronium analyses (since these were administered immediately after the baseline measurement just prior to intubation/commencement of the surgical period)." (NCT00751179)
Timeframe: Baseline and 15 minutes post dose

Interventionmmol/L (Mean)
Rocuronium - Sugammadex0.07

[back to top]

Change From Baseline in Plasma Potassium Levels at 2 Minutes After Treatment With Rocuronium or Succinylcholine

"Change from baseline = 2 minutes post dose value - baseline value. Baseline levels were obtained prior to rocuronium or succinylcholine dose. Only data post rocuronium dose are included for rocuronium - sugammadex group. The change from baseline interval included most or all of the intubation/surgical period for sugammadex analysis (since sugammadex was administered at the end of the surgical procedure) but not for succinylcholine or rocuronium analyses (since these were administered immediately after the baseline measurement just prior to intubation/commencement of the surgical period)." (NCT00751179)
Timeframe: Baseline and 2 minutes post dose

Interventionmmol/L (Mean)
Rocuronium - Sugammadex-0.09
Succinylcholine0.19

[back to top]

Change From Baseline in Plasma Potassium Levels at 2 Minutes After Treatment With Sugammadex

"Change from baseline = 2 minutes post dose value - baseline value. Baseline levels were obtained prior to rocuronium dose. Only data post sugammadex dose are included for rocuronium - sugammadex group. The change from baseline interval included most or all of the intubation/surgical period for sugammadex analysis (since sugammadex was administered at the end of the surgical procedure) but not for succinylcholine or rocuronium analyses (since these were administered immediately after the baseline measurement just prior to intubation/commencement of the surgical period)." (NCT00751179)
Timeframe: Baseline and 2 minutes post dose

Interventionmmol/L (Mean)
Rocuronium - Sugammadex-0.02

[back to top]

Change From Baseline in Plasma Potassium Levels at 5 Minutes After Treatment With Rocuronium or Succinylcholine

"Change from baseline = 5 minutes post dose value - baseline value. Baseline levels were obtained prior to rocuronium or succinylcholine dose. Only data post rocuronium dose are included for rocuronium - sugammadex group. The change from baseline interval included most or all of the intubation/surgical period for sugammadex analysis (since sugammadex was administered at the end of the surgical procedure) but not for succinylcholine or rocuronium analyses (since these were administered immediately after the baseline measurement just prior to intubation/commencement of the surgical period)." (NCT00751179)
Timeframe: Baseline and 5 minutes post dose

Interventionmmol/L (Mean)
Rocuronium - Sugammadex-0.06
Succinylcholine0.30

[back to top]

Change From Baseline in Plasma Potassium Levels at 5 Minutes After Treatment With Sugammadex

"Change from baseline = 5 minutes post dose value - baseline value. Baseline levels were obtained prior to rocuronium dose. Only data post sugammadex dose are included for rocuronium - sugammadex group. The change from baseline interval included most or all of the intubation/surgical period for sugammadex analysis (since sugammadex was administered at the end of the surgical procedure) but not for succinylcholine or rocuronium analyses (since these were administered immediately after the baseline measurement just prior to intubation/commencement of the surgical period)." (NCT00751179)
Timeframe: Baseline and 5 minutes post dose

Interventionmmol/L (Mean)
Rocuronium - Sugammadex0.02

[back to top]

Time to Recovery of T1 to 90% of Baseline Following Neuromuscular Blockade Induced by Succinylcholine

Neuromuscular functioning was monitored by applying repetitive train of four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. Nerve stimulation continued until recovery of T1 of 90% of baseline and full recovery of neuromuscular function occurred as determined by the anesthesiologist as per routine clinical practice. (NCT00751179)
Timeframe: Start of administration of succinylcholine to recovery from neuromuscular blockade (Up to approximately 18 minutes)

InterventionMinutes (Geometric Mean)
Succinylcholine10.76

[back to top]

Time to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9 Following Administration of 4.0 mg/kg of Sugammadex After Neuromuscular Blockade Induced by Rocuronium

Neuromuscular functioning was monitored by applying repetitive train of four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. Nerve stimulation continued until the ratio of the magnitude of the fourth twitch (T4) to first twitch (T1) reached at least 0.9. The greater the T4/T1 ratio the greater the recovery from neuromuscular blockade, with a value of 1.0 representing full recovery. (NCT00751179)
Timeframe: Start of administration of sugammadex to recovery from neuromuscular blockade (Up to approximately 6 minutes)

InterventionMinutes (Geometric Mean)
Rocuronium - Sugammadex1.79

[back to top]

Muscle Pain

"verbal rating scale score and the pain score both at 2 and 24 hours postoperatively.~The verbal rating scale score ranges from 0 (no pain) to 100 (worst pain imaginable).~The pain score ranges from 0 to 3: 0 none; 1 muscle stiffness or pain in the nape of the neck, shoulders, and chest; 2 muscle stiffness and pain requiring analgesia; and 3 incapacitating generalized muscle stiffness or pain." (NCT00986583)
Timeframe: 2 and 24 hours postoperatively

,
Interventionparticipants (Number)
VRS score at 2 hour: 0 (no pain)VRS score at 2 hour: 10-30VRS score at 2 hour: 40-70VRS score at 2 hour: 80-100VRS score at 24 hour: 0 (no pain)VRS score at 24 hour: 10-30VRS score at 24 hour: 40-70VRS score at 24 hour: 80-100Pain score at 2 hour: 0 (no pain)Pain score at 2 hour: 1Pain score at 2 hour: 2Pain score at 24 hour: 0 (no pain)Pain score at 24 hour: 1Pain score at 24 hour: 2
Non Statin Use260422542126332552
Statin Use Group342113421134403440

[back to top]

Plasma Myoglobin Concentration

(NCT00986583)
Timeframe: induction, 5 minutes after administration, 20 minutes and 24 hours post operatively

,
Interventionug/l (Median)
Measurement time = induction (0 minute)Measurement time = 5 minuteMeasurement time = 20 minute (primary)Measurement time = 24 hour
Non Statin Use39494795
Statin Use Group467177137

[back to top]

Serum Potassium Concentration

(NCT00986583)
Timeframe: At 5 and 20 min after succinylcholine

,
InterventionmEq/l (Median)
at 5 minuteat 20 minute
Non Statin Use4.23.9
Statin Use Group4.24.0

[back to top]

Change in Plasma Creatine Phosphokinase (CK) Concentration From 2 to 24 Hours Postoperatively

Change in plasma creatine phosphokinase (CK) concentration from 2 to 24 hours postoperatively (NCT00986583)
Timeframe: 2 and 24 hours postoperatively

Interventionunits/l (Median)
Statin Use Group175
Non Statin Use78

[back to top]

Duration of Succinylcholine Block

Time required to reach maximum block by succinylcholine after succinylcholine administration. (NCT00986583)
Timeframe: intraoperative: from succinylcholine administration

Interventionminute (Median)
Statin Use Group4.2
Non Statin Use4.6

[back to top]

Fasciculation

The fasciculation ranges from 0 to 3: 0 none; 1 small movements around eyes and fingers; 2 moderate movements in face, neck, fingers, and trunk; and 3 vigorous movements in trunk and extremities. (NCT00986583)
Timeframe: postoperative

,
Interventionparticipants (Number)
NoneSmallModerateVigorous
Non Statin Use13388
Statin Use Group961013

[back to top]

Compound Specific Differences in Time to Recovery From Neuromuscular Blockade

The investigators defined the compound specific differences in time to recovery from neuromuscular blockade - i.e., recovery of spontaneous breathing and recovery of the twitch height to baseline. (NCT01441960)
Timeframe: Up to six weeks following inclusion

Interventionminutes (Mean)
Succinylchline9.7
Rocuronium19.5

[back to top]

Differences in Seizure Duration Between Compounds

Observational reports suggest that differences in seizure duration might exist depending on the neuromuscular blocking agents used to accomplish muscle strength control during ECT. (NCT01441960)
Timeframe: Up to six weeks following inclusion

InterventionSeconds (Mean)
Succinylcholine27
Rocuronium31

[back to top]

Optimal Dose of Neuromuscular Blocking Agent During ECT

The optimal dose of muscle neuromuscular blocking is defined as the lowest dose of either compound that predicts 'acceptable' control of muscle strength during ECT. Assessment of the primary end point is based on a dichotomous scale 'acceptable' and 'not acceptable' control of muscle strength during ECT, and the two assessors will be blinded to the dose of neuromuscular blocking agent. The optimal dose was identified for each subject, and results were reported as the average of all lowest doses collected in the study. (NCT01441960)
Timeframe: Up to six weeks following inclusion

Interventionmg.kg-1 (Mean)
NMBA: Sux0.85
NMBA- Rocuronium0.41

[back to top]

Columbia Autobiographical Memory Interview-Short Form (AMI-SF)

The AMI-SF is used to assess retrospective autobiographical memory function. It has six categories, which involve five questions each, about a family member, most recent travel, last New Year's Eve, last birthday, most recent employment and last visit to a doctor for a physical complaint. At baseline interviewers encourage the participant to recall as much information as they can. Responses at baseline can be scored either two points, for a recognisable real memory, or zero for no memory or too little information to constitute a proper memory. Only those questions for which a memory had been retrieved at baseline are examined at follow-up. Follow-up assessments are scored as percentage recall of baseline score, which is scored as 100% irrespective of actual performance.. (NCT01907217)
Timeframe: 3 months follow-up

Intervention% of baseline performance (Mean)
Bilateral ECT Mecta 5000M56.2
High-dose Unilateral ECT Mecta 5000M67.3

[back to top]

Columbia Autobiographical Memory Interview-Short Form (AMI-SF)

The AMI-SF is used to assess retrospective autobiographical memory function. It has six categories, which involve five questions each, about a family member, most recent travel, last New Year's Eve, last birthday, most recent employment and last visit to a doctor for a physical complaint. At baseline interviewers encourage the participant to recall as much information as they can. Responses at baseline can be scored either two points, for a recognisable real memory, or zero for no memory or too little information to constitute a proper memory. Only those questions for which a memory had been retrieved at baseline are examined at follow-up. Follow-up assessments are scored as percentage recall of baseline score, which is scored as 100% irrespective of actual performance.. (NCT01907217)
Timeframe: 6 months follow-up

Intervention% of baseline performance (Mean)
Bilateral ECT Mecta 5000M52.9
High-dose Unilateral ECT Mecta 5000M63.4

[back to top]

Columbia Autobiographical Memory Interview-Short Form (AMI-SF)

The AMI-SF is used to assess retrospective autobiographical memory function. It has six categories, which involve five questions each, about a family member, most recent travel, last New Year's Eve, last birthday, most recent employment and last visit to a doctor for a physical complaint. At baseline interviewers encourage the participant to recall as much information as they can. Responses at baseline can be scored either two points, for a recognisable real memory, or zero for no memory or too little information to constitute a proper memory. Only those questions for which a memory had been retrieved at baseline are examined at follow-up. Follow-up assessments are scored as percentage recall of baseline score, which is scored as 100% irrespective of actual performance.. (NCT01907217)
Timeframe: end of allocated ECT course

Intervention% of baseline performance (Mean)
Bilateral ECT Mecta 5000M56.8
High-dose Unilateral ECT Mecta 5000M67.1

[back to top]

Hamilton Depression Rating Scale (HDRS)

The HDRS was originally designed to assess severity of depressive symptoms in patients with a primary depressive illness and is now the most commonly used measure of depression severity. It was first published in a 17-item format with the optional addition of 4 items making up the 21-item version. In addition to the original 21 items, the 24-item HDRS includes items on helplessness, hopelessness and worthlessness; its score range is 0-77, with higher scores reflecting greater burden of depressive symptoms. (NCT01907217)
Timeframe: HDRS scores were obtained at baseline, end of allocated ECT treatment, and at 3 and 6 month follow-up timepoints.

,
Interventionunits on a scale (Mean)
BaselineEnd-of-treatment3 months follow-up6 months follow-up
Bilateral ECT Mecta 5000M29.512.515.013.0
High-dose Unilateral ECT Mecta 5000M30.411.111.512.6

[back to top]

Number of Participants With Newborn in Need of Respiratory Support

The number of participants with a newborn in need of respiratory support will be the primary safety measure in comparison of the influence of different neuromuscular blockade levels on newborn adaptation. (NCT01941628)
Timeframe: 24 hours

Interventionparticipants (Number)
Rocuronium0
Succinylcholine0

[back to top]

Peroperative and Postoperative Surgical Complication

A total number of surgical complications evaluated at day 5 after Caesarean delivery. (NCT01941628)
Timeframe: 5 days

Interventionparticipants (Number)
Rocuronium0
Succinylcholine0

[back to top]

Induction to Delivery Interval

Induction to delivery interval will be used as primary keypoint for surgical conditions comparison. (NCT01941628)
Timeframe: 24 hrs

Interventionseconds (Mean)
Rocuronium268
Succinylcholine276

[back to top]

Fade on Train of Four Stimulation

We stimulated the ulnar nerve at the wrist four times (over 1.5 seconds) every 20 seconds. We measured the ratio of the fourth contraction to the first contraction before and after the administration of succinylcholine. Before administering succinylcholine the ratio is normally one. After the administration of succinylcholine the first contraction diminishes, but the fourth contraction diminishes even more. This results in a ratio of T4 to T1 being less than one. The lowest ratio recorded after the administration after the administration of succinylcholine is reported as our outcome measure. (NCT02425449)
Timeframe: for the duration of the effect of succinylcholine generally expected to be 6-10 minutes

InterventionRatio (Mean)
Arm 20.85
Arm 30.64
Arm 40.66
Arm 50.68

[back to top]

Surgical Conditions

Assessed by surgeon questionnaire designed for study to determine any negative effects impeding the progress of surgery or safety, on scale of 1=poor to 5=excellent (NCT02635542)
Timeframe: During general anesthesia

Interventionunits on a scale (Mean)
Group CIS4.96
Group SUX4.65

[back to top]

Number of Participants With Postoperative Pulmonary Complications

Having at least one of the following complications, determined according to pre-specified criteria: extubation delayed >24hrs, reintubation, mechanical respiratory support, pneumonia, aspiration, ARDS (Acute Respiratory Distress Syndrome), or mortality from respiratory arrest. (NCT02635542)
Timeframe: 72 hours following surgical procedure

InterventionParticipants (Count of Participants)
Group CIS8
Group SUX8

[back to top]

Last Recorded Train-of-four (TOF) Ratio Before Tracheal Extubation or Removal of Supraglottic Airway Device in Patients Receiving a Non-depolarizing NMBA

The train-of-four (TOF) ratio is the ratio between the last and first measurements after four stimuli of the ulnar nerve at 2 Hz. The ratio should be at least 0.9 before tracheal extubation. (NCT02914119)
Timeframe: in the period from induction of anaesthesia to termination of anaesthesia, usually 2 hours

InterventionTrain-of-four ratio (Median)
Eligible Patients0.97

[back to top]

Time in Minutes From Tracheal Extubation or Removal of Supraglottic Airway Device to Discharge From Post-anaesthesia Care Unit in Cases Involving a Non-depolarizing NMBA With and Without Neuromuscular Monitoring, Respectively

(NCT02914119)
Timeframe: in the period from induction of anaesthesia to discharge from the post-anaesthesia care unit, usually 180 minutes

InterventionMinutes (Median)
Eligible Patients97

[back to top]

Recovery Time of T1 to 90% Baseline

The time of neuromuscular recovery from sugammadex 4mg/kg dose reversal rocuronium at 0.6 mg/kg compared with traditionally used succinylcholine in electroconvulsive therapy (ECT). (NCT03532178)
Timeframe: 30 minutes

Interventionminutes (Mean)
Muscle Relaxant #16.79
Muscle Relaxant #210.97

[back to top]

Number of Participants With Treatment or Emergent Adverse Events of the Drugs

To document the side-effect profiles of sugammadex reversal of rocuronium and succhinylcholine in the ECT patient population (NCT03532178)
Timeframe: 24 hours after the procedure

,
InterventionParticipants (Count of Participants)
NauseaMyalgiaHeadache
Rocuronium + Sugammadex117
Succinylcholine + Normal Saline329

[back to top]